CVS Health To Boost Access To FDA-approved Nasal Naloxone For Patients Without Insurance

By: via Benzinga
CVS Health Inc. (NYSE: CVS) and Adapt Pharma today revealed a fresh alliance to make the opioid overdose-reversing drug NARCAN Nasal ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.